Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

R. Kefford; H. Arkenau; M. P. Brown; M. Millward; J. R. Infante; G. V. Long; D. Ouellet; M. Curtis; P. F. Lebowitz; G. S. Falchook

doi:10.1200/jco.2010.28.15_suppl.8503

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long, D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	8503–8503
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	28
Issue number	15
DOIs	https://doi.org/10.1200/jco.2010.28.15_suppl.8503
Publication status	Published - 20 May 2010

Access to Document

10.1200/jco.2010.28.15_suppl.8503

Cite this

Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010). Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of Clinical Oncology, 28(15), 8503–8503. https://doi.org/10.1200/jco.2010.28.15_suppl.8503

@article{75edcce214dd4537953a4e06e1fb6872,

title = "Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors",

author = "R. Kefford and H. Arkenau and Brown, \{M. P.\} and M. Millward and Infante, \{J. R.\} and Long, \{G. V.\} and D. Ouellet and M. Curtis and Lebowitz, \{P. F.\} and Falchook, \{G. S.\}",

year = "2010",

month = may,

day = "20",

doi = "10.1200/jco.2010.28.15\_suppl.8503",

language = "English",

volume = "28",

pages = "8503–8503",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Kefford, R, Arkenau, H, Brown, MP, Millward, M, Infante, JR, Long, GV, Ouellet, D, Curtis, M, Lebowitz, PF & Falchook, GS 2010, 'Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors', Journal of Clinical Oncology, vol. 28, no. 15, pp. 8503–8503. https://doi.org/10.1200/jco.2010.28.15_suppl.8503

TY - JOUR

T1 - Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

AU - Kefford, R.

AU - Arkenau, H.

AU - Brown, M. P.

AU - Millward, M.

AU - Infante, J. R.

AU - Long, G. V.

AU - Ouellet, D.

AU - Curtis, M.

AU - Lebowitz, P. F.

AU - Falchook, G. S.

PY - 2010/5/20

Y1 - 2010/5/20

U2 - 10.1200/jco.2010.28.15_suppl.8503

DO - 10.1200/jco.2010.28.15_suppl.8503

M3 - Meeting abstract

SN - 0732-183X

VL - 28

SP - 8503

EP - 8503

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -